ous abstinence rate and intervention costs were estimated. a dynamic population model for COPD was used to project the long-term (cost-)effectiveness of one year implementation of minimal counseling, intensive counseling and intensive counseling plus pharmacotherapy for 50% of the smoking COPD patients compared to usual care. Time horizon was 25 years. Uncertainty and one-way sensitivity analyses were performed for variations in (the calculation of) the abstinence rates, the type of projection, intervention costs and discount rates. RESULTS: Nine studies were selected. The average 12 months continuous abstinence rates were estimated to be 1.4% for usual care, 2.6% for minimal counseling, 6.0% for intensive counseling and 12.3% for pharmacotherapy. Compared to usual care, the costs per QALY gained for minimal counseling, intensive counseling and intensive counseling plus pharmacotherapy were c16,900, c8,200 and c2,400, respectively. Results were most sensitive to variations in abstinence rates and discount rates. CONCLUSIONS: Compared to usual care intensive counseling and pharmacotherapy resulted in low costs per QALY gained with ratios comparable to results presented for smoking cessation in the general population. Compared to intensive counseling alone, intensive counseling plus pharmacotherapy was cost saving and dominated the other interventions.
PRS25 A COST-UTILITY ANALYSIS FOR TIOTROPIUM BROMIDE IN THE LONG TERM TREATMENT OF SPECIFIC SUBGROUPS OF ITALIAN COPD PATIENTS
Zaniolo O, Iannazzo S, Carsi M Adres srl, Torino, Italy OBJECTIVES: The UPLIFT trial demonstrated in 5,993 patients with moderate to very-severe chronic obstructive pulmonary disease (COPD) that 4 years of tiotropium bromide were associated with improvements in lung function, quality of life, and exacerbations compared with placebo. The aim of this study is the economic assessment of tiotropium when included in COPD routine care (RC) for specifi c groups of Italian COPD patients. METHODS: A probabilistic patient-level simulation Markov model was developed over a lifetime horizon, with one-year cycles and a 3.5% annual discount rate. Patients were characterized by gender, age, height, smoking status and FEV1. FEV1 time trend was modelled based on the decline recorded in UPLIFT. The mortality of the general Italian population adjusted by smoking status and FEV1 was adopted. Health utilities derived from published Italian studies, while their variation from the UPLIFT. Exacerbation rates derived from an Italian observational prospective study and were adjusted for the relative risk (RR) reported in UPLIFT. Direct sanitary costs were considered. Health care resource consumption for RC, exacerbations and SAEs derived from Italian observational studies and were valued according to current price and tariffs. Cost-effectiveness was assessed for the overall cohort and for subgroups of patients by age, sex, GOLD stage and smoking attitude. RESULTS: In the whole cohort, patients treated with tiotropium gained an average (95%CI) 0.50 (−1.63-−6.27) LYs and 0.42 (−0.25-−3.05) QALYs with respect to RC. The incremental lifetime cost was c3,357 (−c10,669-−c29,820). The incremental cost-effectiveness ratio (ICER) was c7,916 /QALY. In the subgroups analysis the ICER ranged from a minimum of c6,627/QALY (females, GOLD III) to a maximum of c13,187/ QALY (age <65 y, GOLD IV). CONCLUSIONS: The inclusion of tiotropium in RC for moderate to very severe COPD patients represents good value for money in Italy. The analysis across subgroups demonstrated a good stability of the model.
PRS26 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF MOMETASONE FUROATE AS MAINTENANCE TREATMENT IN PATIENTS WITH MILD TO MODERATE ASTHMA FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
Fernandes RA, Takemoto ML, Cukier FN, Guerra FC, Passos RB ANOVA-Knowledge Translation, Rio de Janeiro, RJ, Brazil OBJECTIVES: In the Brazilian public health care system, mometasone furoate (MF DPI) is not available and budesonide/formoterol (BUD/FF DPI) association is responsible for 86.9% of pharmacy claims for asthma. This study aimed to conduct costeffectiveness and budget impact analysis (BIA) of MF versus BUD/FF for adult patients with mild to moderate asthma from the public payer perspective. METHODS: A decision tree was developed to compare MF and BUD/FF based on indirect comparison once head-to-head studies were not available. The fi nal FEV1 values were converted into probabilities of hospitalization in the fi rst two years in accordance with observational evidence of association between FEV1 and exacerbation requiring hospitalization. Only direct medical costs were considered and unit costs were obtained from Brazilian offi cial lists. BIA assumed pharmacy claims data from the Ambulatory Information System as current scenario (Beclomethasone: 3.1%; BUD: 9.9%; BUD/ FF: 86.9%) and a 20% initial market share for MF in substitution to equivalent doses of BUD/FF. RESULTS: Indirect comparison indicated 79 hospitalizations per 1000 patients for MF and 82 for BUD/FF during the fi rst 2 years of treatment. Total cost of treatment was 832BRL and 655BRL per patient for MF200 mcg twice a day (bid) and MF400 mcg once a day and 840BRL for BUD/FF 400/12 mcg bid. These fi ndings indicated MF as cost-saving in the proposed scenario with ICER of −2.608BRL and −61.959BRL per avoided hospitalization for MF200 mcg and MF400 mcg, respectively. The estimated budgetary impact for the fi rst year showed a saving of 259,346,480BRL for MF 400 mcg and 10,919,299BRL for MF 200 mcg. CONCLU-SIONS: MF is a clinically effective option to treat mild to moderate asthma and indirect comparison showed its clinical and economic benefi t when compared to the most used anti-asthma medication in the Brazilian public setting. Further research to directly compare both medications and to measure fi nalistic outcomes alongside clinical trials is needed.
PRS27 COUNTRY ADAPTATION OF A HEALTH ECONOMIC MODEL: THE CASE FOR ROFLUMILAST IN THE NETHERLANDS
Vemer P, Goossens LM, Rutten-Van Mölken MP Erasmus University, Rotterdam, The Netherlands BACKGROUND: The phosphodiesterase-4 enzyme (PDE4) inhibitor rofl umilast is a new treatment that targets the underlying infl ammation associated with COPD. When approved, rofl umilast will be registered as an add-on to bronchodilator treatment in adult patients with severe COPD, with a history of frequent exacerbations. a health economic (HE) micro-simulation Markov model was used to support its submission in the United Kingdom (UK). Pharmaceutical companies can save signifi cantly on the process of HE evidence development, if models can be adapted for use in more than one country. OBJECTIVES: To transfer an existing UK HE model to the The Netherlands in order to calculate the cost-effectiveness (CE) of rofl umilast in patients with severe COPD from a societal perspective. METHODS: The model structure was adapted to include production loss using the friction cost method, and to separate heterogeneity from parameter uncertainty. All input parameters on health care use, costs, utilities, and COPD epidemiology were obtained from Dutch sources, except for the case-fatality rate of an exacerbation-related hospitalization. a direct comparison was made between a combination of a long-acting β2 agonist (LABA) plus rofl umilast (ROFLU) and LABA alone. a second, indirect comparison was between LABA + ROFLU and LABA plus an inhaled corticosteroid (ICS). One-way and probabilistic sensitivity analyses were performed. RESULTS: From a societal perspective, the incremental CE ratio (ICER) for LABA + ROFLU compared with LABA alone, was c7900. The ICER of LABA + ROFLU versus LABA + ICS was c10,000. The probability that LABA + ROFLU was cost-effective when compared with LABA alone at a threshold of c20,000 versus LABA was 97%. Compared with LABA + ICS this probability was 68.3%. CONCLUSIONS: The original UK model was suitable for adaptation to the Dutch setting. The ICERs of rofl umilast were below commonly referred threshold values of a QALY.
PRS28 ECONOMIC EVALUATION OF FLUTICASONE PROPIONATE/ SALMETEROL COMBINATION THERAPY AND MONTELUKAST IN ADULT PATIENTS WHO ARE SYMPTOMATIC ON SHORT-ACTING BETA 2-AGONIST ALONE
Rely K 1 , Gonzalez SE 2 , Salinas GE 3 , Alexandre PK 4 1 CEAHealthTech, Mexico City, D.F., Mexico; 2 GlaxoSmithKline, Mexico City, D.F., Mexico; 3 Hospital Infantil de México Federico Gómez, Mexico City, D.F., Mexico; 4 Johns Hopkins University, Baltimore, MD, USA OBJECTIVES: To estimate the incremental cost-effectiveness of SFC verus montelukast in adult patients with persistent asthma. METHODS: A decision-analytic model was developed from a randomized, double-blind, double-dummy, 12-week clinical trial were analyzed. Effi cacy end points included, symptom-free days (SFDs) during the 12-week period. The study assumed the Mexican health care perspective with costs in 2010 US dollars, and hence only direct costs were included in the analysis. Direct costs included those related to study drugs, emergency room department visits, unscheduled physician visits, and rescue medication. The incremental cost-effectiveness ratio (ICER), which is the mean difference in average costs divided by the mean difference in average effectiveness, was calculated for the effectiveness outcomes (SFDs). Issue of uncertainty was addressed by means of a probabilistic Monte Carlo simulation, which attributed stochastic distributions to model inputs. RESULTS: Treatment with FSC resulted in a signifi cantly greater improvement in the mean percentage of symptom-free days compared with MON 48.9 and 21.7 respectively (p 0.001). In the base case, patients initiated on SFC displayed a 45% reduction in overall cost as compared with patients initiated on MON US S186 versus $US258, respectively, respectively). SFC dominated the use of MON because of previously demonstrated lower incidence of Asthma exacerbations and rescue free days. Sensitivity analyses determined that univariate changes in all model variables, including medication cost, and cost of treating exacerbation, did not impact overall results. a Monte Carlo simulation analysis found that use of SFC remains the best overall treatment strategy when taking into consideration the potential variance in all model assumptions. Compared with MON, SFC is estimated to be both more effective and more economically favourable, with a probability of almost 92%. CONCLUSIONS: The decision model indicated that use of SFC as treatment in patients with asthma should result in lower overall treatment costs relative to the cost of MON.
